Literature DB >> 28296277

Effect of icariin in combination with daily sildenafil on penile atrophy and erectile dysfunction in a rat model of bilateral cavernous nerves injury.

Y Xu1, H Xin2, Y Wu3, R Guan4, H Lei4, X Fu1, Z Xin4, Y Yang3.   

Abstract

The commonly utilized phosphodiesterase type 5 inhibitors do not lead to satisfactory penile erection after radical prostatectomy mainly because of insufficient nitric oxide drive from the damaged cavernous nerves. The aim of this study was to assess the efficacy and mechanisms of icariin in combination with daily sildenafil on neurogenic erectile dysfunction and penile atrophy in a rat model of bilateral cavernous nerves injury. Sixty male Sprague-Dawley rats injected with 5-ethynyl-2-deoxyuridine (50 mg/kg) at postnatal day 1 for the purpose of tracking endogenous stem cells in penis. Forty-eight rats of bilateral cavernous nerves injury were randomized equally into gavage feeding of vehicle, sildenafil (10 mg/kg), icariin (1.5 mg/kg) and sildenafil + icariin, respectively. Twelve sham-operated rats served as control. The intracavernous pressure and mean arterial pressure was measured and mid-penile cross sections were histologically examined 5 weeks after surgery. Western blotting of cavernous tissue protein was also performed. Animals treated with sildenafil + icariin had significantly higher mean intracavernous pressure/mean arterial pressure ratio relative to other rats with bilateral cavernous nerves injury (p < 0.05). The circumference and mean cross-sectional area of the paired corpus cavernosum were effectively preserved in the sildenafil + icariin. Treatment with sildenafil + icariin significantly increased the cavernous cyclic guanosine monophosphate concentration compared with the icariin group (p < 0.05). In addition, the numbers of neuronal nitric oxide synthase-positive nerves and 5-ethynyl-2-deoxyuridine-positive cells co-expressing S100 in the icariin-treated groups were greater compared with the bilateral cavernous nerves injury control group (p < 0.05). These data suggest that the combined use of icariin and daily sildenafil holds promise as a potential therapy for neurogenic erectile dysfunction in the future. The underlying mechanisms appears to involve two aspects: (i) icariin promotes differentiation of endogenous stem cells to Schwann cells, which help to repair the damaged neural pathway for erection; (ii) on this basis, sildenafil can further improve penile engorgement through the cyclic guanosine monophosphate-dependent smooth muscle relaxation.
© 2017 American Society of Andrology and European Academy of Andrology.

Entities:  

Keywords:  cavernous nerve injury; erectile dysfunction; icariin; radical prostatectomy; sildenafil

Mesh:

Substances:

Year:  2017        PMID: 28296277     DOI: 10.1111/andr.12341

Source DB:  PubMed          Journal:  Andrology        ISSN: 2047-2919            Impact factor:   3.842


  4 in total

1.  Randomized, Triple-Blinded, Placebo-Controlled Trial of SA3X (Spilanthes acmella) for the Management of Erectile Dysfunction.

Authors:  Nabnita Patnaik; Kumar Guru Mishra; Nihar Ranjan Pradhan
Journal:  Cureus       Date:  2022-04-09

2.  The Protective Effect of Salidroside on Hypoxia-Induced Corpus Cavernosum Smooth Muscle Cell Phenotypic Transformation.

Authors:  Xiang Zhang; Jian-Feng Zhao; Fan Zhao; Jun-Feng Yan; Fan Yang; Xiao-Jun Huang; Gang Chen; Hui-Ying Fu; Bo-Dong Lv
Journal:  Evid Based Complement Alternat Med       Date:  2017-07-17       Impact factor: 2.629

Review 3.  Deciphering the myth of icariin and synthetic derivatives in improving erectile function from a molecular biology perspective: a narrative review.

Authors:  Yuanjie Niu; Guiting Lin; Jiancheng Pan; Jihong Liu; Yongde Xu; Qiliang Cai; Tao Wang; Yang Luan; Yegang Chen; Yuhong Feng; Xiaoqing Yang; Wenjie Tian; Wong Jin Bae; Ruili Guan; Zhongcheng Xin
Journal:  Transl Androl Urol       Date:  2022-07

4.  Intracavernous injection of size-specific stem cell spheroids for neurogenic erectile dysfunction: Efficacy and risk versus single cells.

Authors:  Yongde Xu; Yong Yang; Han Zheng; Chao Huang; Xiaoming Zhu; Yichen Zhu; Ruili Guan; Zhongcheng Xin; Zhiqiang Liu; Ye Tian
Journal:  EBioMedicine       Date:  2020-02-12       Impact factor: 8.143

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.